Enovachem duloxetine capsules exceed the nitrosamine acceptable intake limit
Duloxetine DR Capsules, 30 mg, relabeled by Enovachem are being recalled over CGMP deviations and N-nitroso-duloxetine above the FDA acceptable intake limit.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for a nitrosamine impurity above its acceptable intake limit, a product-quality failure creating risk of harm with no injuries reported.
Plain-English summary
Duloxetine DR Capsules, 30 mg, in 30-count bottles, relabeled by Enovachem Pharmaceuticals of Torrance, California and marketed by Ajanta Pharma USA Inc., NDC 76420-634-30, are being recalled. The action covers 50 bottles.
The stated reasons are current good manufacturing practice deviations and the presence of a Nitrosamine Drug Substance Related Impurity, N-nitroso-duloxetine, above the FDA acceptable intake limit. Nitrosamine impurities are controlled to defined intake limits because of their potential for long-term harm. The FDA classified the action as Class II.
Affected lots are 050725G-30 and 050725F-30, expiry 06/30/2026. Distribution was US nationwide.
This is a prescription medicine. Patients should not stop taking a prescribed course without medical advice; anyone holding an affected lot should contact their pharmacy or prescriber about a replacement supply.
The recalled product
- Product
- DULOXETINE (DULOXETINE)
- Brand
- DULOXETINE
- Manufacturer
- Asclemed USA Inc.
- Category
- Drug — Delayed-release capsule
- Affected units
- 50
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 050725G-30 & 050725F-30
- Exp Date: 06/30/2026
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DULOXETINE
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- ModerateDuloxetine Delayed-Release Capsules 20 mg Recalled for Impurity
FDA (Drugs) · 2026-05-13
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateDuloxetine Delayed-Release Capsules Recalled for Impurity Above FDA Limit
FDA (Drugs) · 2026-05-13
Same manufacturer · Asclemed USA Inc.
See all →- LowLIDOLOG KIT Drug Recall Over Barcode Label Wrap Issue
FDA (Drugs) · 2026-07-29
- SevereAccucaine Lidocaine Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-08
- SevereLidocaine Hydrochloride Injection Recalled for Sterility Assurance
FDA (Drugs) · 2026-07-08
Same hazard · nitrosamine impurity
See all →- HighCipla cinacalcet 90 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 30 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 60 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighPrazosin hydrochloride further lots recalled over nitrosamine impurity levels
FDA (Drugs) · 2026-04-08
- HighPrazosin hydrochloride 100-count bottles recalled over nitrosamine impurity
FDA (Drugs) · 2026-04-08